Prevention of RSV disease in babies starts at HUS hospitals
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody developed against the RS virus called nirsevimab to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is offered to all children born after August 1, 2024. HUS will offer nirsevimab to newborns in all its maternity hospitals from October 23, 2024. Children under the age of one year at risk for severe disease will be offered nirsevimab at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 4, 2024, until the end of November.
The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024
Nirsevimab is effective in preventing RSV infections
A long-acting antibody called nirsevimab is used to prevent RSV infections. It is administered as a single intramuscular injection. Nirsevimab is safe to administer even to newborns, and it provides efficient protection against RSV for the entire winter epidemic.
The product is very safe. It has been in use in several countries during the winter 2023–2024, where it prevented 80–90% of hospitalizations caused by RSV.
Keywords
Contacts
Director Jari Petäjä, p. 050 428 6630, jari.petaja@hus.fi
HUS Children and adolecents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-yhtymän osavuosikatsaus tammi–syyskuu 202512.11.2025 14:11:02 EET | Tiedote
HUS-yhtymän osavuosikatsaus tammi−syyskuu 2025: HUS etenemässä ensimmäisenä julkisena sotepe-toimijana kohti talouden tasapainotusta ja alijäämien kattamista lain vaatimalla tavalla ja aikataulussa.
Hälsobyn är Årets digitala tjänst 20256.11.2025 17:40:35 EET | Nyheter
Hälsobyn har utsetts till Årets digitala tjänst 2025. Utmärkelsen delas ut till en betydande nationell tjänst som har haft en positiv inverkan på det finländska samhället och medborgarnas liv.
Terveyskylä on Vuoden Digipalvelu 20256.11.2025 17:40:35 EET | Uutinen
Terveyskylä on valittu vuoden 2025 digipalveluksi. Vuoden Digipalvelu -palkinto myönnetään merkittävälle kansalliselle palvelulle, joka on vaikuttanut positiivisesti suomalaiseen yhteiskuntaan ja kansalaisten elämään.
HUS inleder substitutionsbehandling för opioidberoende hos unga – beredskap för behandling redan i höst6.11.2025 08:54:13 EET | Pressmeddelande
Inom HUS ungdomspsykiatri införs substitutionsbehandling för opioidberoende som en ny behandlingsform. Användningen av opioider bland unga har blivit allt vanligare och hälsoriskerna förknippade med det är betydande. Vården grundar sig på nationella rekommendationer som utarbetats i samarbete med sakkunniga vid universitetssjukhusen.
Nuorten opioidikorvaushoito käynnistyy HUSissa – hoitoon valmius jo tänä syksynä6.11.2025 08:54:13 EET | Tiedote
HUSin Nuorisopsykiatriassa otetaan käyttöön uutena hoitomuotona opioidikorvaushoito. Nuorten opioidien käyttö on yleistynyt, ja siihen liittyvät terveysriskit ovat merkittäviä. Hoito perustuu kansalliseen suositukseen, joka on laadittu yhteistyössä yliopistosairaaloiden asiantuntijoiden kanssa.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom